The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Open accessAbstract
Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. However, the actual benefit of the upfront exposure to the three cytotoxic drugs compared with a preplanned sequential strategy of doublets was not clear, and neither was the feasibility or efficacy of therapies after disease progression. We aimed to compare a preplanned strategy of upfront FOLFOXIRI followed by the reintroduction of the same regimen after disease progression versus a sequence of mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) and FOLFIRI doublets, in combination with bevacizumab.Methods TRIBE2 was an open-label, phase 3, randomised study of patients aged 18-75 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 2, with unresectable, previously untreated metastatic colorectal cancer, recruited from 58 Italian oncology units. Patients were stratified according to centre, ECOG performance status, primary tumour location, and previous adjuvant chemotherapy. A randomisation system incorporating a minimisation algorithm was used to randomly assign patients (1:1) via a masked web-based allocation procedure to two different treatment strategies. In the control group, patients received first-line mFOLFOX6 (85 mg/m 2 of intravenous oxaliplatin concurrently with 200 mg/m 2 of leucovorin over 120 min; 400 mg/m 2 intravenous bolus of fluorouracil; 2400 mg/m 2 continuous infusion of fluorouracil for 48 h) plus bevacizumab (5 mg/kg intravenously over 30 min) followed by FOLFIRI (180 mg/m 2 of intravenous irinotecan over 120 min concurrently with 200 mg/m 2 of leucovorin; 400 mg/m 2 intravenous bolus of fluorouracil; 2400 mg/m 2 continuous infusion of fluorouracil for 48 h) plus bevacizumab after disease progression. In the experimental group, patients received FOLFOXIRI (165 mg/m 2 of intravenous irinotecan over 60 min; 85 mg/m 2 intravenous oxaliplatin concurrently with 200 mg/m 2 of leucovorin over 120 min; 3200 mg/m 2 continuous infusion of fluorouracil for 48 h) plus bevacizumab followed by the reintroduction of the same regimen after disease progression. Combination treatments were repeated every 14 days for up to eight cycles followed by fluorouracil and leucovorin (at the same dose administered at the last induction cycle) plus bevacizumab maintenance until disease progression, unacceptable adverse events, or consent withdrawal. Patients and investigators were not masked. The primary endpoint was progression-free survival 2, defined as the time from randomisation to disease progression on any treatment given after first disease progression, or death, analysed by intention to treat. Safety was assessed in patients who received at least one dose of their assigned treatment. Study recruitment is complete and follow-up is ongoing. This trial is registered with Clinicaltrials.gov, NCT02339116.Findings Between Feb 26, 2015, and May 15, 2017, 679 patients were randomly assigned and received treatment (340 in the control group and 339 in the experimental group). At data cut-off (July 30, 2019) median follow-up was 35·9 months (IQR 30·1-41·4). Median progression-free survival 2 was 19·2 months (95% CI 17·3-21·4) in the experimental group and 16·4 months (15·1-17·5) in the control group (hazard ratio [HR] 0·74, 95% CI 0·63-0·88; p=0·0005). During the first-line treatment, the most frequent of all-cause grade 3-4 events were diarrhoea (57 [17%] vs 18 [5%]), neutropenia (168 [50%] vs 71 [21%]), and arterial hypertension (25 [7%] vs 35 [10%]) in the experimental group compared with the control group. Serious adverse events occurred in 84 (25%) patients in the experimental group and in 56 (17%) patients in the control group. Eight treatment-related deaths were reported in the experimental group (two intestinal occlusions, two intestinal perforations, two sepsis, one myocardial infarction, and one bleeding) and four in the control group (two occlusions, one perforation, and one pulmonary embolism). After first disease progression, no substantial differences in the incidence of grade 3 or 4 adverse events were reported between the control and experimental groups, with the exception of neurotoxicity, which was only reported in the experimental group (six [5%] of 132 patients). Serious adverse events after disease progression occurred in 20 (15%) patients in the experimental group and 25 (12%) in the control group. Three treatment-related deaths after first disease progression were reported in the experimental group (two intestinal occlusions and one sepsis) and four in the control group (one intestinal occlusion, one intestinal perforation, one cerebrovascular event, and one sepsis).Interpretation Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the same regimen after disease progression seems to be a preferable therapeutic strategy to sequential administration of chemotherapy doublets, in combination with bevacizumab, for patients with metastatic colorectal cancer selected according to the study criteria.Funding The GONO Cooperative Group, the ARCO Foundation, and F Hoffmann-La Roche.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The results showed a significant advantage for upfront FOLFOXIRI plus bevacizumab in terms of PFS2 with an mPFS2 of 19.1 months vs. 16.4 months for the comparator arm (HR 0.74, p < 0.001).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y., Cooper, H. S., Deming, D. A., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,333
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092
Self-citationInitial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062
Self-citationVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationSimkens, L. H. J., van Tinteren, H., May, A. M., ten Tije, A. J., Creemers, G., Loosveld, O. J. L., de Jongh, F. E., Erdkamp, F., Erjavec, Z., van der Torren, A. M. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62004-3 · Cited by 526
Stintzing, S., Modest, D. P., Rossius, L., Lerch, M. M., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30269-8 · Cited by 420
Cited by
Sorted by citations
Items 201–300 of 334
Faisal, M. S., Hussain, I., Ikram, M. A., Shah, S. B., Rehman, A., & Iqbal, W. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2349444 · Cited by 5
Zhou, Y., Wu, S., & Qu, F.-J. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i6.2362 · Cited by 3
Bellio, H., Roussot, N., Bertaut, A., Hervieu, A., Zanetta, S., Tharin, Z., Vincent, J., Bengrine-Lefèvre, L., Hennequin, A., Guion, J.-F., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2461446 · Cited by 3
Prognostic analysis of patients with CRLM based on CRS score: a single-center retrospective study
Xue, J.-S., Maimaitiming, N., Zhang, B.-L., Xu, B., Yin, X., Huang, Z. J., Che, X., Zhao, H., & Cai, J.-Q. (2025) · BMC Cancer · doi:10.1186/s12885-025-14135-7 · Cited by 3
Antoniotti, C., Marmorino, F., Rossini, D., Schmoll, H., Lonardi, S., Tonini, G., Borelli, B., Cupini, S., Stein, A., Moretto, R., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115713 · Cited by 3
Self-citationStahler, A., Heinemann, V., Holch, J. W., von Einem, J. C., Westphalen, C. B., Heinrich, K., Schlieker, L., Jelas, I., Alig, A. H. S., Fischer, L. E., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33747 · Cited by 5
Value of Geriatric Assessment in Patients With Genitourinary Carcinoma
Zangl, Q. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0620 · Cited by 3
Shi, H., Chen, Y., Huang, C., Li, C., Su, W., Chang, T., Chen, P.-J., Yin, T., Tsai, H., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.756078 · Cited by 3
Age-related trends in the incidence of metastatic colorectal cancer from 2010 to 2019 in the USA
Vassilev, Z. P., Guo, H., Lin, W., Xu, J., Khan, N., & Fan, X. (2023) · Future Oncology · doi:10.2217/fon-2023-0376 · Cited by 3
Moretto, R., Rossini, D., Murgioni, S., Ciracì, P., Nasca, V., Germani, M. M., Calegari, M. A., Vetere, G., Intini, R., Taravella, A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00329 · Cited by 3
Self-citationSatake, H., Ando, K., Oki, E., Shimokawa, M., Makiyama, A., Saeki, H., Tsuji, A., & Mori, M. (2020) · BMC Cancer · doi:10.1186/s12885-020-07576-9 · Cited by 4
Fedyanin, M. Y., Максимовна, П. Е., Elsnukaeva, H., Tryakin, A. A., Покатаев, И. А., Bulanov, A., & Tjulandin, S. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-20-125-132 · Cited by 3
Seufferlein, T. T. W., Lausser, L. M., Stein, A., Arnold, D., Prager, G. W., Kasper, S., Niedermeier, M., Müller, L., Kubicka, S., König, A. O., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304324 · Cited by 2
Inukai, M., Nishi, T., Matsuoka, H., Matsuo, K., Suzuki, K., Serizawa, A., Akimoto, S., Nakauchi, M., Tanaka, T., Kikuchi, K., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12813-6 · Cited by 2
van Nassau, S. C. M. W., Zwart, K., van der Baan, F. H., Vink, G. R., Elferink, M. A. G., Snæbjörnsson, P., May, A. M., Koopman, M., & Roodhart, J. M. L. (2025) · International Journal of Cancer · doi:10.1002/ijc.35410 · Cited by 2
Colorectal cancer liver metastases: immune environment and therapeutic perspectives
Wen, J., Jiang, J., Zhang, J., Wu, Z., Hu, D. X., Wang, W., Zhang, Z., & Xia, L. (2025) · Gastrointestinal Tumors · doi:10.48130/git-0025-0002 · Cited by 2
Shan, H., Huang, S., Zhou, C., Wang, M., & Du, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1631022 · Cited by 2
Weiss, L., Stintzing, S., Modest, D. P., Stahler, A., von Weikersthal, L. F., Reinacher‐Schick, A., Decker, T. W., Probst, V., Heinrich, K., Schwaner, I., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116105 · Cited by 3
Nardo, P. D., de Scordilli, M., Giudici, F., Basile, D., Pastò, B., Rota, S., Torresan, S., Bortolot, M., Foltran, L., Guardascione, M., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag011 · Cited by 2
Self-citationWu, J., & Zhang, L. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156480 · Cited by 2
Fan, J., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, J., Xu, R., Ye, Y., 张苏展, et al. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00062-6 · Cited by 2
Fanotto, V., Rossini, D., Casagrande, M., Bergamo, F., Spagnoletti, A., Santini, D., Antoniotti, C., Cupini, S., Daniel, F., Nasca, V., et al. (2023) · Cancers · doi:10.3390/cancers15225451 · Cited by 2
Self-citationVarnier, R., Toullec, C., Philonenko, S., Dupré, A., Artru, P., Hafliger, É., Drouillard, A., Torregrosa, C., Pernot, S., McLellan, P., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.02.009 · Cited by 2
Chen, Y., Zhu, D., Yu, Y., Chang, W., Ye, L., Feng, Q., Xu, P., Chen, M., Ji, M., Wei, Y., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.006 · Cited by 3
Jiang, Y., Zhao, M., Tang, W., & Zheng, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1293598 · Cited by 2
Keshavarzi, F., Salari, N., Jambarsang, S., Tabatabaei, S. M., Shahsavari, S., & Fournier, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36464 · Cited by 2
Wei, G.-X., Zhou, Y., Dong, C., Zhang, T., Cao, P., Xie, L., & Qiu, M. (2024) · BMC Cancer · doi:10.1186/s12885-024-13171-z · Cited by 2
McKigney, N., Seligmann, J. F., Twiddy, M., Bach, S. P., Mohamed, F., Fearnhead, N. S., Brown, J. M., & Harji, D. P. (2025) · Trials · doi:10.1186/s13063-025-08811-z · Cited by 2
Survival in stage IV colorectal cancer at diagnosis
Chang, J., Dornbush, C., Mott, S. L., Loeffler, B. T., Guyton, K. L., Hrabe, J. E., & Gribovskaja‐Rupp, I. (2025) · Surgical Oncology Insight · doi:10.1016/j.soi.2025.100144 · Cited by 2
Li, S., Dong, D., Zheng, X., Wang, H., Wang, K., Xing, B., & Wang, W. (2025) · Current Oncology · doi:10.3390/curroncol32060347 · Cited by 2
Zhao, J., Zhu, J., Sun, R., Huang, C., Yuan, R., & Zhu, Z. (2021) · BMC Cancer · doi:10.1186/s12885-021-08157-0 · Cited by 2
Cheng, Y., Wu, G., Zhang, S., Liu, Y., Qu, J., & Qu, X. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s320477 · Cited by 2
Pharmacotherapy for unresectable metastatic colorectal cancer
Rogers, J. E., & Dasari, A. N. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1982895 · Cited by 2
Carlsson, G. U., Koumarianou, A. A., Guren, T. K., Haux, J., Katsaounis, P., Kentepozidis, N. K., Pfeiffer, P., Brændengen, M., Mavroudis, D., Taflin, H. A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100589 · Cited by 2
BRAF Testing in Melanoma and Colorectal Cancer in Latin America: Challenges and Opportunities
Peixoto, R. D., Chakhtoura, J. J. A., Rivello, H. G., Jansen, A. M., Medina, R. P., & Stefani, S. D. (2022) · Cureus · doi:10.7759/cureus.31972 · Cited by 2
Jiang, Y., Fu, X.-Y., & Yin, Z. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i5.906 · Cited by 2
COLOMATE challenge to overcome resistance in metastatic colorectal cancer
Yoshino, T. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0656 · Cited by 2
Initial Systemic Chemotherapy for Metastatic Colorectal Cancer
Yu, I. S., Advani, S., & Kopetz, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_31 · Cited by 1
Qu, W., Sun, Y., Zhang, W., Jiang, Z., Han, Y., Jin, J., Xue, Q., & Zhou, A. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13918 · Cited by 1
Cook, J. A. (2023) · doi:10.1093/med/9780198885238.003.0003 · Cited by 1
Tsai, H., Huang, C.-W., Chen, Y., Su, W., Chang, T., Chen, P.-J., Li, C., Chang, Y., & Wang, J. (2023) · Medicina · doi:10.3390/medicina59122108 · Cited by 1
Bando, H., Kotani, D., Satake, H., Hamaguchi, T., Shiozawa, M., Kotaka, M., Masuishi, T., Yasui, H., Kagawa, Y., Komatsu, Y., et al. (2024) · Med · doi:10.1016/j.medj.2024.05.012 · Cited by 1
Systemic Therapy for Metastatic Colon Cancer: New Frontiers
Pumpalova, Y. S. (2024) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0044-1787826 · Cited by 2
Chapin, W. J., Hwang, W., Mamtani, R., & O’Hara, M. H. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100087 · Cited by 1
Yamamoto, Y., Yukami, H., Yamaguchi, T., Ohori, H., Nagasu, S., Kagawa, Y., Sugimoto, N., Sonoda, H., Yamazaki, K., Takashima, A., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02613-0 · Cited by 1
Liu, X., Wu, S., Dang, W., Shen, H., Sun, M., Chen, Y., Zhang, Z., Li, M., Cai, Z., Wang, H., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2430160 · Cited by 1
Bagrezaei, F., Gargari, B. P., Zamiri, R. E., Safaiyan, A., & Alizadeh, M. (2025) · BMC Cancer · doi:10.1186/s12885-025-13538-w · Cited by 1
Ando, K., Satake, H., Shimokawa, M., Yasui, H., Negoro, Y., Kinjo, T., Kizaki, J., Baba, K., Orita, H., Hirata, K., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02701-9 · Cited by 1
Zhang, Q., Li, L., & Qian, X. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2471058 · Cited by 1
Liu, T., Yao, Y., Liu, B., Teng, X., Dong, M., & Zhang, X. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2509706 · Cited by 1
Targeting γδ T cells for immunotherapies against colorectal cancer
Mikulak, J., Marzano, P., Cazzetta, V., & Mavilio, D. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.11.009 · Cited by 1
Eade, A. V., Smith, E. C., Monge, C., Hannah, C. E., Skorupan, N., Hrones, D. M., Celades, C., Goswami, M., Bagheri, H., Smith, K. M., et al. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00173 · Cited by 1
Clinically Meaningful Outcome Measures: A Role for Geriatric Assessment
Kovar, N. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0624 · Cited by 1
Kemps, S., Soleyman, M., Huls, H., Labots, M., & Crul, M. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-003215 · Cited by 1
Lara-Morga, C., Palka-Kotlowska, M., Custodio‐Cabello, S., Pacheco-Barcía, V., & Cabezón‐Gutiérrez, L. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00136 · Cited by 1
Metastasiertes kolorektales Karzinom – moderne Therapiestrategien und -sequenzen
Ettrich, T. J., Schuhbaur, J., & Seufferlein, T. T. W. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01516-y · Cited by 1
Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer
Grandhi, N., Patel, B. G., & Aranha, O. (2023) · Seminars in Colon and Rectal Surgery · doi:10.1016/j.scrs.2023.100972 · Cited by 1
Recent Research Progress in Targeted Ther-apy of Metastatic Colorectal Cancer
张, 婷. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361445 · Cited by 1
Zhang, X., Ma, H., He, Y., He, W., Chen, N., Li, Y., Zhong, W., Wu, G. S., Zhou, X., Hua, H., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225035 · Cited by 1
The New Perspectives Journal of Medicine
(2024) · The New Perspectives Journal of Medicine · doi:10.5582/npjm.2023.01228
Low- vs High-Dose 5-FU in Triplet Chemotherapy Plus Bevacizumab for Patients With Colorectal Cancer
Chapin, W. J., Hwang, W., Mamtani, R., & O’Hara, M. H. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.24855 · Cited by 1
Wang, Q., Zhong, J., Wang, Y., Jun, B., Li, S., & Liu, Y. (2025) · American Journal of Case Reports · doi:10.12659/ajcr.946757 · Cited by 1
Phillips, W. J., Marginean, H., Alrehaili, M., Abdelrahim, A. A., Asmis, T., Vickers, M., Yeung, B., Lo, B., & Goodwin, R. A. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100896 · Cited by 2
Li, X., Bao, J., & Ma, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-086372 · Cited by 2
Chen, J., Yu, W., Xia, X., Zhao, Y., Tang, Q., Zhang, Y., Zhang, Y., Zhang, H., Zhang, Z., Zhang, X., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1570457 · Cited by 1
Khatib, J., & Kainthla, R. (2020) · Current Colorectal Cancer Reports · doi:10.1007/s11888-020-00455-2 · Cited by 1
Gizhlaryan, M. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0665 · Cited by 1
Molecular profiling in colorectal cancer
Piringer, G. (2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00833-6 · Cited by 1
Avallone, A., & Giuliani, F. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30273-4 · Cited by 1
TRIBE2 results and toxicity – Authors' reply
Antoniotti, C., Cremolini, C., Rossini, D., & Falcone, A. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30288-6 · Cited by 1
Self-citationZhang, J., Cai, Y., Xie, X., Hu, H., & Deng, Y. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30270-9
Hype and hope of hepatic arterial infusion for colorectal cancer
Ghiringhelli, F. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-20-756
Képénékian, V., Villeneuve, L., & Gléhen, O. (2020) · Côlon & Rectum · doi:10.3166/cer-2020-0163
58/w mit Stuhlgangunregelmäßigkeiten und Druckgefühl im rechten Oberbauch
Stein, A. (2021) · Der Onkologe · doi:10.1007/s00761-021-01028-0
祐太郎, 久. (2021) · Institutional Repositories DataBase (IRDB) · doi:10.14930/jshowaunivsoc.81.139
A roadmap for medical treatment of metastatic CRC
Martínez-Bernal, G., Martínez‐Pérez, J., & Valladares‐Ayerbes, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00016-8
Cusano, E., Wong, C., Taguedong, E., Vaska, M. M., Abedin, T., Nixon, N. A., Karim, S., Tang, P. A., Heng, D. Y. C., & Ezeife, D. A. (2021) · Current Oncology · doi:10.3390/curroncol28060412
Immunotherapy in the Treatment of Advanced Colorectal Cancer
Raman, P., Botrus, G., & Bekaii‐Saab, T. (2022) · Cancer immunotherapy · doi:10.1007/13905_2021_12
FOLFOXIRI plus Bevacizumab beim metastasierten kolorektalen Karzinom
(2021) · TumorDiagnostik & Therapie · doi:10.1055/a-1379-2612
Efficacy in randomised trials: the time matters
Ottaiano, A., Santorsola, M., Caraglia, M., & Nasti, G. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00187-5 · Cited by 1
Diagnostik und Therapie des Kolonkarzinoms
Bisang, U., Zeitz, J., Groth, S., von Allmen, M., Schneider, P. M., & Samaras, P. (2022) · Schweizer Gastroenterologie · doi:10.1007/s43472-022-00081-3
Knitter, S., Duwe, G., Beierle, A. S., Pesthy, S., Ritschl, P. V., Hillebrandt, K. H., Arnold, A., Malinka, T., Modest, D. P., Bahra, M., et al. (2022) · Cancers · doi:10.3390/cancers14235992
Marsh, R. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_35
Treatment Refractory Metastatic Colorectal Cancer
Huey, R. W., & Raghav, K. P. S. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_32
58/w mit Stuhlgangunregelmäßigkeiten und Druckgefühl im rechten Oberbauch
Stein, A. (2023) · best practice onkologie · doi:10.1007/s11654-023-00479-8
Current treatment options for BRAF V600E mutant metastatic colorectal cancer
Liberko, M., & Soumarová, R. (2023) · Onkologie · doi:10.36290/xon.2023.062
Management of Metastic Liver Cancer
Stewart, C. L., Ho, F., Fong, Y., Davis, S. L., Lisa, L., Lindquist, J. D., Karukonda, P., Willett, C. G., & Czito, B. G. (2024) · Wiley eBooks · doi:10.1002/9781119756422.ch19
Metastasiertes kolorektales Karzinom – moderne Therapiestrategien und -sequenzen
Ettrich, T. J., Schuhbaur, J., & Seufferlein, T. T. W. (2024) · Die Onkologie · doi:10.1007/s00761-024-01489-z
First Line Chemotherapy in Metastatic Colorectal Cancers: A Review
Colombo, A., Bordonaro, R., Sciacchitano, T., & Porretto, C. M. (2024) · International Journal of Advanced Multidisciplinary Research and Studies · doi:10.62225/2583049x.2024.4.2.2556
Self-citationPrognostic and Predictive Factors in Metastatic Colorectal Cancer
Österlund, E. (2024) · doi:10.33063/diva-522642
How to treat liver metastases in colorectal cancer: A review
Colombo, A., & Porretto, C. M. (2024) · International Journal of Gastrointestinal Intervention · doi:10.18528/ijgii240046
Takahashi, T., Ishii, T., Maejima, T., Miyazaki, D., Fukahori, S., Kuwahara, H., Aimono, E., Kimura, T., Yanai, M., & Hagiwara, M. (2024) · Cancer Reports · doi:10.1002/cnr2.70051
Li, J., Ba, Y., Lin, R., Ke, X. Y., yin, X., Ying, J., Cheng, Y., Xu, N., Xu, J., Shen, Y., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.10.003
Tougeron, D., Emile, J., Bodère, A., Barbier, E., Perrier, H., Corbinais, S., Brun-Ly, V. L., Bideau, K., Chibaudel, B., Khemissa, F., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5046191
Phillips, W. J., Marginean, H., Alrehaili, M., Abdelrahim, A. A., Asmis, T., Vickers, M., Yeung, B., Lo, B., & Goodwin, R. A. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5120377
Giannini, R., Ucciero, A., Romagnoli, A., Musicco, F., Santoleri, F., Abrate, P., Isgrò, V., Costantini, A., & Lasala, R. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251355434
Colloca, G. A., & Venturino, A. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2536107
Tsukushi, Y., Koriyama, K., Kobuchi, S., Matsumoto, K., Ιtο, Y., & Sakaeda, T. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04801-9
Mine, K., Kawashiri, T., Mori, Y., Fujita, S., Uchida, M., Yamada, T., Egashira, N., Ieiri, I., Koyanagi, S., Ohdo, S., et al. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70054
Metadata
- Authors
- Cremolini, C., Antoniotti, C., Rossini, D., Lonardi, S., Loupakis, F., Pietrantonio, F., Bordonaro, R., Latiano, T. P., Tamburini, E., Santini, D., Passardi, A., Marmorino, F., Grande, R., Aprile, G., Zaniboni, A., Murgioni, S., Granetto, C., Buonadonna, A., Moretto, R., Corallo, S., Cordio, S., Antonuzzo, L., Tomasello, G., Masi, G., Ronzoni, M., Di Donato, S., Carlomagno, C., Clavarezza, M., Ritorto, G., Mambrini, A., Roselli, M., Cupini, S., Mammoliti, S., Fenocchio, E., Corgna, E., Zagonel, V., Fontanini, G., Ugolini, C., Boni, L., Falcone, A., Falcone, A., Lonardi, S., De Braud, F. G. M., Bordonaro, R., Maiello, E., Tamburini, E., Santini, D., Frassineti, G. L., Gamucci, T., Aprile, G., Zaniboni, A., Granetto, C., Buonadonna, A., Di Costanzo, F., Tomasello, G., Gianni, L., Di Donato, S., Carlomagno, C., Clavarezza, M., Racca, P., Mambrini, A., Roselli, M., Allegrini, G., Sobrero, A., Aglietta, M., Corgna, E., Cortesi, E., Corsi, D. C., Ballestrero, A., Bonetti, A., Di Clemente, F., Ruggeri, E., Ciardiello, F., Benasso, M., Vitello, S., Cinieri, S., Mosconi, S., Silvestris, N., Frassoldati, A., Cupini, S., Bertolini, A., Tortora, G., Bengala, C., Ferrari, D., Ardizzoia, A., Milandri, C., Chiara, S., Romano, G., Miraglia, S., Scaltriti, L., Pucci, F., Blasi, L., Brugnatelli, S., Fioretto, L., Ribecco, A. S., Longarini, R., Frisinghelli, M., & Banzi, M.
- Affiliations
- University of Pisa (IT)
- University of Milan (IT)
- Casa Sollievo della Sofferenza (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Ospedale Garibaldi (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- IRCCS Ospedale San Raffaele (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Ospedale di Livorno (IT)
- Ospedale Policlinico San Martino (IT)
- Candiolo Cancer Institute (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Federico II University Hospital (IT)
- ORCID
- Cremolini, Chiara
- Antoniotti, Carlotta
- Rossini, Daniele
- Loupakis, Fotios
- Pietrantonio, Filippo
- Latiano, Tiziana Pia
- Passardi, Alessandro
- Marmorino, Federica
- Murgioni, Sabina
- Moretto, Roberto
- Corallo, Salvatore
- Antonuzzo, Lorenzo
- Masi, Gianluca
- Ronzoni, Monica
- Mammoliti, Serafina
- Fenocchio, Elisabetta
- Zagonel, Vittorina
- Fontanini, Gabriella
- Ugolini, Clara
- Boni, Luca
- Maiello, Evaristo
- Frassineti, Giovanni Luca
- Sobrero, Alberto
- Aglietta, Massimo
- Cortesi, Enrico
- Corsi, Domenico Cristiano
- Ballestrero, Alberto
- Bonetti, Andrea
- Ruggeri, Enzo
- Ciardiello, Fortunato
- Vitello, Stefano
- Cinieri, Saverio
- Mosconi, Stefania
- Silvestris, Nicola
- Frassoldati, Antonio
- Tortora, Giampaolo
- Ferrari, Daris
- Blasi, Livio
- Brugnatelli, Silvia
- Fioretto, Luisa
- Banzi, Maria
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 497-507
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3009139795
- Cited by
- 334
- References
- 39
- Citations by year
- 2026: 35 · 2025: 45 · 2024: 50 · 2023: 53 · 2022: 53 · 2021: 67 · 2020: 31
- FWCI
- 18.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.thelancet.com
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, FOLFOXIRI, FOLFIRI, mFOLFOX6, bevacizumab, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, first-line chemotherapy, sequential chemotherapy
- MeSH terms
- Bevacizumab, Antineoplastic Agents, Immunological, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Disease Progression, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
